TL;DR
This study reveals a surprising mechanism by which SARS-CoV-2 exploits dimeric IgA (dIgA) antibodies, which are typically thought to be protective, to enhance its infection and cause more severe damage in the nasal passages. This finding challenges the conventional understanding of IgA's role in mucosal immunity against respiratory viruses and suggests new avenues for therapeutic strategies.
What Problem Does This Paper Address?
The high transmissibility of SARS-CoV-2, particularly through the upper respiratory tract, remains a critical challenge for pandemic control. While neutralizing antibodies, especially IgG, have been extensively studied for their therapeutic potential, the role of IgA, a key player in mucosal immunity, in controlling SARS-CoV-2 infection, especially in the nasal turbinate (NT), has been less clear. Specifically, it was unknown whether IgA antibodies could effectively neutralize the virus in the nasal cavity and prevent infection and subsequent damage. This paper investigates how different forms of IgA antibodies, engineered from a potent neutralizing IgG, behave in vivo against SARS-CoV-2 nasal challenge.
Methods
The researchers engineered a potent neutralizing IgG antibody (B8-IgG1) into various IgA forms: monomeric IgA1 (B8-mIgA1), monomeric IgA2 (B8-mIgA2), dimeric IgA1 (B8-dIgA1), and dimeric IgA2 (B8-dIgA2). They then evaluated these antibodies in a Syrian hamster model of intranasal SARS-CoV-2 infection. Key techniques included:
- In vitro characterization: ELISA and pseudovirus neutralization assays were used to confirm the binding and neutralizing activities of the engineered IgA antibodies.
- In vivo challenge studies: Hamsters were treated with the antibodies (prophylactically or therapeutically) and then challenged with live SARS-CoV-2. Viral loads were assessed using plaque assays (PFU) and RT-PCR for viral RNA. Tissue damage was evaluated through histological analysis and immunofluorescence staining for viral nucleocapsid protein (NP).
- Mechanism investigation: To understand how dIgA might enhance infection, researchers investigated the role of CD209 (DC-SIGN) as an alternative entry receptor and performed cell-cell fusion assays.
- Cryo-EM analysis: This technique was used to determine the structural basis of B8 antibody binding to the SARS-CoV-2 spike protein, revealing its binding mode and epitope.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Dimeric IgA's Unexpected Role: The most striking finding is that dimeric IgA antibodies (B8-dIgA1 and B8-dIgA2), while potent neutralizers in vitro, paradoxically enhanced SARS-CoV-2 infection and caused more severe damage in the nasal turbinate of hamsters, unlike monomeric IgA or IgG.
- Hijacking CD209 for Entry: Virus-bound dIgA antibodies appear to engage CD209, a receptor found on cells that do not express ACE2 (the primary SARS-CoV-2 entry receptor), facilitating viral entry into these alternative cell types.
- Facilitating Cell-to-Cell Transmission: This dIgA-mediated entry into CD209+ cells seems to promote viral spread, potentially through trans-infection mechanisms, leading to enhanced nasal infection and injury.
- Structural Basis of Neutralization: Cryo-EM analysis revealed that the B8 antibody binds to the Receptor Binding Motif (RBM) of the SARS-CoV-2 spike protein in a manner consistent with Class II neutralizing antibodies, and this binding site overlaps with ACE2 binding.
Key Results
- Intranasal administration of B8-dIgA1 or B8-dIgA2 led to an 81-fold increase in infectious viruses and more severe damage in the nasal turbinate compared to placebo.
- While B8-IgG1 and monomeric IgA forms showed some suppression of viral load in the lungs, they were less effective in the nasal turbinate.
- Dimeric IgA antibodies (B8-dIgA1 and B8-dIgA2) were found to enhance SARS-CoV-2 infection in cells expressing CD209 but not ACE2.
- Cryo-EM structures showed that B8 binds to the SARS-CoV-2 spike protein in both "3-up" and "2-up/1-down" RBD conformations.
Limitations and Future Work
- Hamster Model: The findings are based on a Syrian hamster model, and it remains to be determined if similar mechanisms occur in humans. The authors suggest further studies are needed to investigate CD209+ DC recruitment in human nasal mucosa during SARS-CoV-2 infection.
- NTD-specific IgA: The study did not include NTD-specific neutralizing IgA for comparison.
- Other Receptors: The role of other cellular receptors, such as the polymeric immunoglobulin receptor (pIgR), in dIgA-enhanced infection was not explored.
- Vaccine/Treatment Implications: It is unknown whether dIgA-mediated enhancement could occur in individuals vaccinated or treated with IgA, and future studies are needed to address this.
- Future Directions: The authors suggest investigating other classes of neutralizing IgA and exploring the role of pIgR. They also highlight the need for future studies to address the limitations mentioned above, particularly regarding human relevance and potential implications for vaccination and therapeutic interventions.
Summary updated